SEC Form 4 · accession 0001144204-17-065710
UNIVERSAL BIOSENSORS INC · UBI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
VF High Conviction Fund
10% Owner
Period of report
Dec 22, 2017
Accepted (ET)
Dec 29, 2017 · 7:33 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001279695
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F6,F7 | Dec 22, 2017 | P | 33,613 | $0.269 | A | 10,577,064 | D | |
| Common StockF1,F3,F6,F7 | Dec 27, 2017 | P | 56,245 | $0.289 | A | 10,633,309 | D | |
| Common StockF1,F4,F6,F7 | Dec 28, 2017 | P | 50,374 | $0.294 | A | 10,683,683 | D | |
| Common StockF1,F5,F6,F7 | Dec 29, 2017 | P | 750,318 | $0.30 | A | 11,434,001 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Traded as Chess Depository Interests ("CDIs") on the Australian Stock Exchange. CDIs represent beneficial interests in the common stock held by CHESS Depository Nominees Pty Ltd.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.265 to $0.270, inclusive. The Reporting Person undertakes to provide to Universal Biosensors, Inc. ("UBI"), any security holder of UBI, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.275 to $0.300, inclusive. The Reporting Person undertakes to provide to Universal Biosensors, Inc. ("UBI"), any security holder of UBI, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.290 to $0.300, inclusive. The Reporting Person undertakes to provide to Universal Biosensors, Inc. ("UBI"), any security holder of UBI, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions all at a price of $0.300. The Reporting Person undertakes to provide to Universal Biosensors, Inc. ("UBI"), any security holder of UBI, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
- F6The price per share of the common stock reported is stated in Australian dollars, as converted from a U.S. dollar price on the date of the transaction.
- F7The common stock is directly held by VF High Conviction Fund ("Conviction Fund") and indirectly held by Viburnum Funds Pty Ltd ("Viburnum"), the manager of Conviction Fund, and the individual directors of Viburnum (Viburnum and the individual directors together, the "Viburnum Indirect Reporting Persons"). The individual directors of Viburnum are Craig Coleman, Marshall Allen, Anthony Howarth and Melissa Karlson. The Viburnum Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the Conviction Fund common stock in which the Viburnum Indirect Reporting Persons have no pecuniary interest.